Medtronic Stock News

Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves more experienced names on Wall Street make.

Medtronic (MDT 0.12%) is a medical device company with vast and diverse operations. Its business is fairly stable although the stock's returns haven't been all that great.

Dividend growth remains robust for select companies, with Casey's, Oil-Dri, and Matson poised for double-digit increases based on strong earnings and expansion. Caterpillar and Kroger are expected to deliver mid-to-high single-digit dividend hikes, reflecting solid but moderating earnings and macroeconomic headwinds. Target and John Wiley will likely announce minimal dividend increases, as flat...

The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, making it attractive for conservative income investors. Medtronic provides a reliable 3.5% yield, a strong balance sheet, and growth catalysts in cardiac solutions, surgical robotics, and a value-e...

Over the past few years, Medtronic (MDT 0.80%) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its fastest-growing segments.

Medtronic plc (NYSE:MDT ) Bernstein's 41st Strategic Decisions Conference Call May 29, 2025 11:00 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Thierry Pieton - Executive Vice President and Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right. Very good.

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

A quarter of a century of increasing dividends is a hell of a way to generate some passive income. Enter Dividend Aristocrats.